F
Femasys
Femasys is engaged in R&D and manufacture of medical devices for women's healthcare
About Femasys
Femasys is a biomedical company that develops and commercializes non-surgical, minimally-invasive, and in-office solutions for women's health.
The company's product portfolio includes FemBloc for permanent birth control and FemVue for infertility diagnosis. These products are designed to be safer, more accessible, and more cost-effective than traditional surgical procedures. Femasys aims to address a significant unmet need in the women's health market by providing solutions that can be administered in a physician's office, reducing the need for hospitalization and general anesthesia.
The company's business model is focused on the development and commercialization of its proprietary technologies. Femasys generates revenue through the sale of its products to physicians and healthcare providers. The target market for Femasys' products includes gynecologists, obstetricians, and other healthcare professionals who specialize in women's health.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2021
News
Open roles
Femasys in the Duluth ecosystem
The Femasys office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Legacy Capital Partners
Series B and later2 investors entered at this stage
PharmaCyte Biotech- NMNantahala Capital Management
Source: Dealroom Talent Intelligence.
See Femasys on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

